Anti-Rheumatic Drugs - Eastern Asia

Eastern Asia

In Eastern Asia, the Anti-Rheumatic Drugs market is expected to witness significant growth in the coming years.
By 2024, the projected revenue for this market is estimated to reach US$4.61bn.
This growth is expected to continue with an annual growth rate (CAGR 2024-2029) of 1.14%, resulting in a market volume of US$4.88bn by 2029.
When compared globally, United States is anticipated to generate the highest revenue in this market, amounting to US$34,700.00m in 2024.
In Eastern Asia, the demand for anti-rheumatic drugs is on the rise due to the high prevalence of rheumatic diseases in the region.

Key regions: Germany, United States, India, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Rheumatic Drugs has been steadily increasing in Eastern Asia due to various factors.

Customer preferences: Patients in Eastern Asia prefer non-invasive treatments for Rheumatoid Arthritis (RA) and Osteoarthritis (OA) which has led to an increase in the demand for Anti-Rheumatic Drugs. Additionally, the aging population in the region has contributed to the increase in demand for these drugs.

Trends in the market: Japan is the largest market for Anti-Rheumatic Drugs in Eastern Asia due to the high prevalence of RA and OA in the country. The market is expected to grow due to the introduction of new drugs and the increasing demand for biologics. South Korea and China are also expected to witness significant growth in the market due to the rising prevalence of RA and OA in these countries.

Local special circumstances: In Japan, the government has implemented regulations to control the pricing of drugs which has led to a decrease in the prices of Anti-Rheumatic Drugs. In China, the government has implemented policies to encourage the development of local pharmaceutical companies which has led to an increase in the production of generic drugs.

Underlying macroeconomic factors: The increasing aging population in Eastern Asia has led to a rise in the prevalence of RA and OA which has contributed to the growth of the Anti-Rheumatic Drugs market. Additionally, the rising healthcare expenditure in the region has led to an increase in the accessibility of these drugs to the patients. The growing awareness about the benefits of early diagnosis and treatment of RA and OA has also contributed to the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.